Trial Profile
A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen (Primary) ; Goserelin; Triptorelin
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms SOFT
- 06 Jun 2023 Secondary analysis evaluating the prognostic and predictive ability of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 15 Dec 2022 Results (n=4690) assessing the 12-year SOFT-TEXT late treatment effects on distant recurrence-free interval and overall survival and benefits in women with human epidermal growth factor receptor 2 negative tumors and in those at high risk of disease relapse, published in the Journal of Clinical Oncology.
- 09 Dec 2022 12-Year results of adjuvant endocrine therapy assessing efficacy in premenopausal breast cancer patients, published in the Journal of Clinical Oncology.